Therefore, we cannot establish whether mycobacteriosis and pulmonary aspergillosis were secondary to the immunosuppression following infliximab treatment rather than resulting from the primary impairment of NF-κB signaling. This evidence concerns the gene NFKB1 and aspergillosis.